Nitya Nanda. The Energy and Resources Institute (TERI)

Similar documents
Carnegie Endowment for International Peace

TRIPS and Access to Medicines. WR Briefing

An overview of India's approach to key IP issues at home and abroad. Dr. Bona Muzaka King s College London

Flexibilities in the Patent System

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

Virtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12:

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.

Changing role of the State in Innovative Activity The Indian Experience. Sunil Mani

Observations from Pharma

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs

AAAS Project on Science and Intellectual Property in the Public Interest

Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

Flexibilities in the Patent System

19 Progressive Development of Protection Framework for Pharmaceutical Invention under the TRIPS Agreement Focusing on Patent Rights

Intellectual Property

Why intellectual property can be a barrier to TT

INTELLECTUAL PROPERTY (IP) SME SCOREBOARD 2016

INTELLECTUAL PROPERTY (IP) SME SCOREBOARD 2016

5 th Annual Pharma IPR Conference 2016

Gujarat Technological University Invites Application for Admission in 1 nd Batch of 6 month Certification course of

Issues at the Intersection of IP and Competition Policy

Chapter 8. Technology and Growth

ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.

Role of Patents in Green Technology Transfer in the Context of Climate Change

Research Patents in Biotech SMEs

SHORT SUMMARY REPORT OF THE WORKSHOP ON GENETIC INVENTIONS, INTELLECTUAL PROPERTY RIGHTS AND LICENSING PRACTICES

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

Sustainable development

Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities

A HOLISTIC APPROACH TO TECHNOLOGY LICENSING IN THAILAND

Innovation Office. Intellectual Property at the Nelson Mandela University: A Brief Introduction. Creating value for tomorrow

Chapter No 6. Research Design and Methodology

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward

Topic 2: The Critical Role of IP Policies in Modern Economies

Patents and Business Strategies A Patent Attorney s Perspective

Presented at GIZ/SAWTEE Training on IPR 1-2 March 2012, Laltipur. Ratnakar Adhikari South Asia Watch on Trade, Economics and Environment

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

International IP. Prof. Eric E. Johnson. General Principles

Issues and Possible Reforms in the U.S. Patent System

TRIPS-Plus Provisions and Access to Technologies:

Economics of IPRs and patents

Identifying and Managing Joint Inventions

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

The TRIPS Tightrope public health, innovation, incentives and access

Business Partnerships in Agriculture and Biotechnology that Advance Early-State Technology

The TRIPS Agreement and Patentability Criteria


The role of IP and other enabling factors for innovation and uptake of climate relevant technologies WIPO Green technology database and services

Patents and Intellectual Property

Intellectual Property and Technology Transfer

372 index. predominantly for supply of domestic market 113, 132 3, 184 5, 186; remedying anticompetitive

Welcome to the Tuesday 17th June 2014

COMPETITIVE INTELLIGENCE USING INTELLECTUAL PROPERTY INFORMATION

Resilient Innovation for Economic Transformation

Slide 25 Advantages and disadvantages of patenting

ACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY

Technology Commercialization Primer: Understanding the Basics. Leza Besemann

A POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA)

WHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO

Establishing a Development Agenda for the World Intellectual Property Organization

INTEGRATING INNOVATION AND CREATIVITY INTO NATIONAL POLICIES AND STRATEGIES OGADA T.

Patents and Clean Energy Technologies in Africa

Research Paper 45 April 2012 CLIMATE CHANGE, TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS: CONTEXT AND RECENT NEGOTIATIONS.

Jagadguru Sri Shivarathreeshwara University (Deemed University) Accredited A Grade by NAAC ONE DAY SEMINAR

Slide 15 The "social contract" implicit in the patent system

Building a Competitive Edge: Protecting Inventions by Patents and Utility Models

Engr. VIRGINIA F. AUMENTADO Patent Information Analytics and Technology Monitoring Division (PATMD)

International Patent Regime. Michael Blakeney

WORLD TRADE ORGANIZATION ADVANCED COURSE. WIPO-WTO/ADV/ACAD/13/INF1.PROV ORIGINAL: English DATE: XXXX

Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence?

TRIPS Post Grant Flexibilities: Key Exceptions to Patent Holders' Rights. David Vivas Eugui

WORLD TRADE ORGANIZATION

Introduction to IP: Some Basics of Patents, Trademarks, & Trade Secrets

The Contribution of Intellectual Property to Facilitating the Transfer of Environmentally Sound Technology

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

strong patents, weak patents and evergreening: should patents for drugs be challenged more often? Giancarlo Del Corno Studio Legale Sena e Tarchini

Patents An Introduction for Owners

Access to Medicines, Patent Information and Freedom to Operate

Study of Comparative Advantages of Chinese and Indian Pharmaceutical Industries under Globalization

UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications November

COLLABORATIVE R&D & IP ISSUES IN TECHNOLOGY TRANSFER IN UNIVERSITY SYSTEM

WIPO-IFIA INTERNATIONAL SYMPOSIUM ON THE COMMERCIALIZATION OF INVENTIONS IN THE GLOBAL MARKET

The Green Economy: Trade and Sustainable Development Implications. From Rio to Rio:Technology Transfer, Innovation and Intellectual Property

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS

WIPO-WTO Colloquium for Teachers of Intellectual Property

Access to Technology in the Post-2015 Development Agenda. Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center

PATENTS FOR CHEMICALS, PHARMACEUTICALS AND BIOTECHNOLOGY

Globalizing IPR Protection: How Important Might RTAs Be?

The role of IP in economic development: the case of China

executives are often viewed to better understand the merits of scientific over commercial solutions.

Government Role for Technology Transfer

China: Managing the IP Lifecycle 2018/2019

TRIPS FLEXIBILITIES AND ACCESS TO MEDICINES

INTELLECTUAL PROPERY RIGHTS: ECONOMY Vs SCIENCE &TECHNOLOGY. Sankar Narayanan.S System Analyst, Anna University Coimbatore

UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview

Creating a more open, inclusive and equitable innovation system.

Transcription:

Nitya Nanda The Energy and Resources Institute (TERI)

Arguments for and against patent protection The climate change context Perspectives on IPR and technology transfer Patent regimes in developing countries Select cases: biotechnology, solar power and wind power Concluding remarks

Innovation is a public good and hence marginal cost is zero => without IPR there will be no R&D o Patent gives monopoly right and hence makes innovation inaccessible to a large number of people o If there is no sufficient checks and balances, the very objective of granting patent rights is defeated why should the state promote innovation when it does not help people? o Provision for compulsory licensing and other remedial measures Without IPR, the innovators will not disclose the knowledge which will adversely affect further R&D and innovation o In reality, companies do not disclose everything. They continue to use both IPR and trade secrets in combination, depending on the situation o In patents, winner takes all. Nobody else is allowed to develop same or similar technology, even if done independently

Patents are used not only for protection of knowledge but also for trade, reputation and strategic competitive tools Patent does not guarantee commercial application of knowledge but exclusion of others from using the same We are in a one product many knowledge (and many patents) situation Too many people are excluded from too many things - rise of anti-commons patent thickets making available knowledge unusable

Access to Patented knowledge as well as full utilization is a concern Internalization of the patent regime has raised further concerns Tools like compulsory licensing and compulsory patent pooling (forcing multiple patent holders to work together) become difficult to use Access to existing knowledge research exemption often not adequate - Patenting of research tools particularly in biotechnology, nanotechnology etc., - knowledge created through research exemption faces commercialization hindrances

Dr I Potrykus developed technology of enriching rice with ß-carotene with support from Rockefeller Foundation 70 different patents held by 40 different owners required Dr Potrykus transferred the right to Syngenta who bought rights from other relevant IPR owners Humanitarian use : o Use in low-income, food-deficit countries (FAO) by farmers with an annual income of less than US$10K o selling without any surcharge for the technology o where national sales are allowed by such farmers, and where re-use of harvested seed is allowed. Will commercial entities take up such research?

India wants UNFCCC COP to address IPR related barriers to technology transfer in climate related technologies (both existing and future) Studies shown emission can be reduced significantly by using existing technologies Many technologies would be of great help in adaptation to CC as well There have been technology denials companies refused to license technologies Example of TRIPS and public health campaign, Doha Declaration and subsequent TRIPS amendment is quoted Did not pick as much momentum as the issue is not as

Developed countries argue that lack of strong intellectual property rights protection in developing countries is one of the major factors for technologies not spreading They also argue that technology transfer does not mean that hi-tech goods should be produced in developing countries, if they have access to such goods, then that is good enough Developing countries argue that IPR is one of the barriers Developing countries should be able to produce these goods and only then these goods would be cheap enough for wide use

Do people respect IPR in developing countries? NO Are there rampant infringement of patent rights? NO Violations are quite common in copyrights, trademarks, designs etc. but not in patents Why? o Not all knowledge in public domain (patented) but partly kept as trade secret o Poor absorption capacity (partly due to denial of technology over long time) o Costs/risks are very high

Qualitative Assessment: Biotech, Wind and Solar power

Genesis in generic pharmaceuticals industry: Biogenerics generic therapeutic products Outsourcing, including contract research activities Agri-biotech dominated by foreign companies Indian biotechnology industry is still at a nascent stage more of generic-focused rather than innovative researchoriented but this is changing Three types of players: o Established local companies who diversify to BT operations o Multinationals (active mainly in agri bio which they dominate; R&D in home country) and o Start up companies with major focus on BT, many of them are in services like contract research and clinical trials

Indian biotech industry is dominated by medical biotechnology. But agricultural biotechnology segment is dominated by one company or rather just one product as Bt Cotton accounts for about 90 percent of the revenue in this segment High export orientation as it earns about 60% of its revenue from the export markets. Bio agri and bio industrial segments are domestic market oriented Some companies see US and EU as their potential markets. There are products invented by Indian companies already in US and EU markets but not in India There are many non-transgenic biotech products particularly bio-fertilizers and bio-pesticides that are not able to get appropriate place in the market

Access to patented knowledge is an important issue/concern for the development of biotechnology industry in India Some companies/research institutes avoid some areas of research as they are over-patented and getting license would not be easy Indian patentatibilty criteria is quite strict which gives some flexibility to potential innovators Indian scientists often find out a new process to avoid the hassles of getting licence to patented knowledge which might not be the most cost effective and time-saving way Patent infringement might be occurring due to low level of awareness among the researchers In India researchers have not been too enthusiastic about patenting their work which meant that their work remain less publicized and hence less prone to charges of infringement

Indian patentatibilty criteria is quite strict which gives some flexibility to potential innovators Indian scientists often find out a new process to avoid the hassles of getting licence to patented knowledge which might not be the most cost effective and time-saving way Patent infringement might be occurring due to low level of awareness among the researchers In India researchers have not been too enthusiastic about patenting their work which meant that their work remain less publicized and hence less prone to charges of infringement Medical biotechnology had initial advantage in bio-generics but agricultural biotechnology did not have such advantage

Largely driven by policies and regulatory incentives Technologies came from outside almost no domestic R&D Technologies came as black box and crucial components are imported Upfront technology costs and royalties are not too high, creating the impression that costs of technology transfers are not too high important components are imported with high costs, hiding the actual costs of import of technology Some companies bought foreign companies with high prices to acquire IPR/technology Little attention to adapt technology to local situations Imported technology is good for low temperature and dust free environment with consistent wind speed and direction In India breakdown rate is high making it less efficient and less reliable

Largely driven by policies and regulatory incentives Technologies used are quite old and off-patent Mostly photovoltaic cell based which cannot take us too far particularly for grid-interactive power generation Solar thermal technology is still expensive and not much in the hands of Indian companies Technologies are not always IPR protected, large part is also subject to trade secret

Quantitative Assessment: Agro-biotech, Wind and Solar Power

90 80 70 60 50 40 30 20 10 0 Ag Bio Wind Solar Own Market Standardized Licensed

25 20 15 10 5 0 Ag Bio Wind Solar Successful Unsuccessful Collaboration

70 60 50 40 30 20 10 0 Ag Bio Wind Solar Yes No Did not try

Patents can promote innovation but with significant adverse effects Market and patent based innovation promotion policies can ignore problems that need more attention in developing countries IPR creates obstacles and adaptation of technologies to local conditions may be ignored Dominance by large corporations (with the help of IPR) can create path dependence and can dump technologies that are not the best suited and drive away better (more appropriate technologies) Absorption capacity is an important factor that affects technology transfer India needs and IP policy rather than an IPR policy and IPR can be a small part of it